Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 104

1.

Recruitment of BRCA1 limits MYCN-driven accumulation of stalled RNA polymerase.

Herold S, Kalb J, Büchel G, Ade CP, Baluapuri A, Xu J, Koster J, Solvie D, Carstensen A, Klotz C, Rodewald S, Schülein-Völk C, Dobbelstein M, Wolf E, Molenaar J, Versteeg R, Walz S, Eilers M.

Nature. 2019 Mar;567(7749):545-549. doi: 10.1038/s41586-019-1030-9. Epub 2019 Mar 20.

PMID:
30894746
2.

Chromatin modifiers Mdm2 and RNF2 prevent RNA:DNA hybrids that impair DNA replication.

Klusmann I, Wohlberedt K, Magerhans A, Teloni F, Korbel JO, Altmeyer M, Dobbelstein M.

Proc Natl Acad Sci U S A. 2018 Nov 27;115(48):E11311-E11320. doi: 10.1073/pnas.1809592115. Epub 2018 Nov 9.

3.

Loss of CHD1 causes DNA repair defects and enhances prostate cancer therapeutic responsiveness.

Kari V, Mansour WY, Raul SK, Baumgart SJ, Mund A, Grade M, Sirma H, Simon R, Will H, Dobbelstein M, Dikomey E, Johnsen SA.

EMBO Rep. 2018 Oct;19(10). pii: e46783. doi: 10.15252/embr.201846783. No abstract available.

4.

CDK4 inhibition diminishes p53 activation by MDM2 antagonists.

Sriraman A, Dickmanns A, Najafova Z, Johnsen SA, Dobbelstein M.

Cell Death Dis. 2018 Sep 11;9(9):918. doi: 10.1038/s41419-018-0968-0.

5.

Correction: Strong antitumor synergy between DNA crosslinking and HSP90 inhibition causes massive premitotic DNA fragmentation in ovarian cancer cells.

Kramer D, Stark N, Schulz-Heddergott R, Erytch N, Edmunds S, Roßmann L, Bastians H, Concin N, Moll UM, Dobbelstein M.

Cell Death Differ. 2019 Mar;26(4):780. doi: 10.1038/s41418-018-0190-8.

6.

Therapeutic Ablation of Gain-of-Function Mutant p53 in Colorectal Cancer Inhibits Stat3-Mediated Tumor Growth and Invasion.

Schulz-Heddergott R, Stark N, Edmunds SJ, Li J, Conradi LC, Bohnenberger H, Ceteci F, Greten FR, Dobbelstein M, Moll UM.

Cancer Cell. 2018 Aug 13;34(2):298-314.e7. doi: 10.1016/j.ccell.2018.07.004.

7.

Inhibition of MAPKAPK2/MK2 facilitates DNA replication upon cancer cell treatment with gemcitabine but not cisplatin.

Li Y, Köpper F, Dobbelstein M.

Cancer Lett. 2018 Aug 1;428:45-54. doi: 10.1016/j.canlet.2018.04.030. Epub 2018 Apr 25.

PMID:
29704518
8.

Mdm2 as a chromatin modifier.

Wienken M, Moll UM, Dobbelstein M.

J Mol Cell Biol. 2017 Feb 1;9(1):74-80. doi: 10.1093/jmcb/mjw046. Review.

9.

Strong antitumor synergy between DNA crosslinking and HSP90 inhibition causes massive premitotic DNA fragmentation in ovarian cancer cells.

Kramer D, Stark N, Schulz-Heddergott R, Erytch N, Edmunds S, Roßmann L, Bastians H, Concin N, Moll UM, Dobbelstein M.

Cell Death Differ. 2017 Feb;24(2):300-316. doi: 10.1038/cdd.2016.124. Epub 2016 Nov 11. Erratum in: Cell Death Differ. 2019 Mar;26(4):780.

10.

p53 Activity Results in DNA Replication Fork Processivity.

Klusmann I, Rodewald S, Müller L, Friedrich M, Wienken M, Li Y, Schulz-Heddergott R, Dobbelstein M.

Cell Rep. 2016 Nov 8;17(7):1845-1857. doi: 10.1016/j.celrep.2016.10.036.

11.

Loss of CHD1 causes DNA repair defects and enhances prostate cancer therapeutic responsiveness.

Kari V, Mansour WY, Raul SK, Baumgart SJ, Mund A, Grade M, Sirma H, Simon R, Will H, Dobbelstein M, Dikomey E, Johnsen SA.

EMBO Rep. 2016 Nov;17(11):1609-1623. Epub 2016 Sep 5. Erratum in: EMBO Rep. 2018 Oct;19(10):.

12.

Fortifying p53 - beyond Mdm2 inhibitors.

Sriraman A, Li Y, Dobbelstein M.

Aging (Albany NY). 2016 Sep 29;8(9):1836-1837. doi: 10.18632/aging.101073. No abstract available.

13.

Cooperation of Nutlin-3a and a Wip1 inhibitor to induce p53 activity.

Sriraman A, Radovanovic M, Wienken M, Najafova Z, Li Y, Dobbelstein M.

Oncotarget. 2016 May 31;7(22):31623-38. doi: 10.18632/oncotarget.9302.

14.

LTR12 promoter activation in a broad range of human tumor cells by HDAC inhibition.

Krönung SK, Beyer U, Chiaramonte ML, Dolfini D, Mantovani R, Dobbelstein M.

Oncotarget. 2016 Jun 7;7(23):33484-97. doi: 10.18632/oncotarget.9255.

15.

MDM2 Associates with Polycomb Repressor Complex 2 and Enhances Stemness-Promoting Chromatin Modifications Independent of p53.

Wienken M, Dickmanns A, Nemajerova A, Kramer D, Najafova Z, Weiss M, Karpiuk O, Kassem M, Zhang Y, Lozano G, Johnsen SA, Moll UM, Zhang X, Dobbelstein M.

Mol Cell. 2016 Jan 7;61(1):68-83. doi: 10.1016/j.molcel.2015.12.008. Epub 2015 Dec 31.

16.

Usp22 deficiency impairs intestinal epithelial lineage specification in vivo.

Kosinsky RL, Wegwitz F, Hellbach N, Dobbelstein M, Mansouri A, Vogel T, Begus-Nahrmann Y, Johnsen SA.

Oncotarget. 2015 Nov 10;6(35):37906-18. doi: 10.18632/oncotarget.5412.

17.

Mdm2 inhibition confers protection of p53-proficient cells from the cytotoxic effects of Wee1 inhibitors.

Li Y, Saini P, Sriraman A, Dobbelstein M.

Oncotarget. 2015 Oct 20;6(32):32339-52. doi: 10.18632/oncotarget.5891.

18.

Corrigendum: Improving survival by exploiting tumour dependence on stabilized mutant p53 for treatment.

Alexandrova EM, Yallowitz AR, Li D, Xu S, Schulz R, Proia DA, Lozano G, Dobbelstein M, Moll UM.

Nature. 2015 Nov 19;527(7578):398. doi: 10.1038/nature15720. Epub 2015 Sep 30. No abstract available.

PMID:
26416737
19.

G2E3 attenuating replicative stress.

Schmidt F, Karnitz LM, Dobbelstein M.

Aging (Albany NY). 2015 Aug;7(8):527-8. No abstract available.

20.

MicroRNA-101 Suppresses Tumor Cell Proliferation by Acting as an Endogenous Proteasome Inhibitor via Targeting the Proteasome Assembly Factor POMP.

Zhang X, Schulz R, Edmunds S, Krüger E, Markert E, Gaedcke J, Cormet-Boyaka E, Ghadimi M, Beissbarth T, Levine AJ, Moll UM, Dobbelstein M.

Mol Cell. 2015 Jul 16;59(2):243-57. doi: 10.1016/j.molcel.2015.05.036. Epub 2015 Jul 2.

21.

Wee1 and Chk1 - crosstalk between key players in replicative stress.

Saini P, Li Y, Dobbelstein M.

Genes Cancer. 2015 May;6(5-6):182-3. No abstract available.

22.

Comprehensive identification of genes driven by ERV9-LTRs reveals TNFRSF10B as a re-activatable mediator of testicular cancer cell death.

Beyer U, Krönung SK, Leha A, Walter L, Dobbelstein M.

Cell Death Differ. 2016 Jan;23(1):64-75. doi: 10.1038/cdd.2015.68. Epub 2015 May 29.

23.

Improving survival by exploiting tumour dependence on stabilized mutant p53 for treatment.

Alexandrova EM, Yallowitz AR, Li D, Xu S, Schulz R, Proia DA, Lozano G, Dobbelstein M, Moll UM.

Nature. 2015 Jul 16;523(7560):352-6. doi: 10.1038/nature14430. Epub 2015 May 25. Erratum in: Nature. 2015 Nov 19;527(7578):398.

24.

Wee1 is required to sustain ATR/Chk1 signaling upon replicative stress.

Saini P, Li Y, Dobbelstein M.

Oncotarget. 2015 May 30;6(15):13072-87.

25.

Exploiting replicative stress to treat cancer.

Dobbelstein M, Sørensen CS.

Nat Rev Drug Discov. 2015 Jun;14(6):405-23. doi: 10.1038/nrd4553. Epub 2015 May 8. Review.

PMID:
25953507
26.

5-Fluorouracil sensitizes colorectal tumor cells towards double stranded DNA breaks by interfering with homologous recombination repair.

Srinivas US, Dyczkowski J, Beißbarth T, Gaedcke J, Mansour WY, Borgmann K, Dobbelstein M.

Oncotarget. 2015 May 20;6(14):12574-86.

27.

Endothelial p53 deletion improves angiogenesis and prevents cardiac fibrosis and heart failure induced by pressure overload in mice.

Gogiraju R, Xu X, Bochenek ML, Steinbrecher JH, Lehnart SE, Wenzel P, Kessel M, Zeisberg EM, Dobbelstein M, Schäfer K.

J Am Heart Assoc. 2015 Feb 24;4(2). pii: e001770. doi: 10.1161/JAHA.115.001770.

28.

A pro-apoptotic function of iASPP by stabilizing p300 and CBP through inhibition of BRMS1 E3 ubiquitin ligase activity.

Kramer D, Schön M, Bayerlová M, Bleckmann A, Schön MP, Zörnig M, Dobbelstein M.

Cell Death Dis. 2015 Feb 12;6:e1634. doi: 10.1038/cddis.2015.17.

29.

Overcoming EMT-driven therapeutic resistance by BH3 mimetics.

Keitel U, Scheel C, Dobbelstein M.

Oncoscience. 2014 Nov 5;1(11):706-8. eCollection 2014.

30.

Screening analysis of ubiquitin ligases reveals G2E3 as a potential target for chemosensitizing cancer cells.

Schmidt F, Kunze M, Loock AC, Dobbelstein M.

Oncotarget. 2015 Jan 20;6(2):617-32.

31.

Bcl-xL mediates therapeutic resistance of a mesenchymal breast cancer cell subpopulation.

Keitel U, Scheel A, Thomale J, Halpape R, Kaulfuß S, Scheel C, Dobbelstein M.

Oncotarget. 2014 Dec 15;5(23):11778-91.

32.

UDP glucuronosyltransferase 1A expression levels determine the response of colorectal cancer cells to the heat shock protein 90 inhibitor ganetespib.

Landmann H, Proia DA, He S, Ogawa LS, Kramer F, Beißbarth T, Grade M, Gaedcke J, Ghadimi M, Moll U, Dobbelstein M.

Cell Death Dis. 2014 Sep 11;5:e1411. doi: 10.1038/cddis.2014.378.

33.

TAp73 is essential for germ cell adhesion and maturation in testis.

Holembowski L, Kramer D, Riedel D, Sordella R, Nemajerova A, Dobbelstein M, Moll UM.

J Cell Biol. 2014 Mar 31;204(7):1173-90. doi: 10.1083/jcb.201306066. Epub 2014 Mar 24.

34.

Targeting tumour-supportive cellular machineries in anticancer drug development.

Dobbelstein M, Moll U.

Nat Rev Drug Discov. 2014 Mar;13(3):179-96. doi: 10.1038/nrd4201. Review.

PMID:
24577400
35.

The MAPK-activated protein kinase 2 mediates gemcitabine sensitivity in pancreatic cancer cells.

Köpper F, Binkowski AM, Bierwirth C, Dobbelstein M.

Cell Cycle. 2014;13(6):884-9. doi: 10.4161/cc.28292. Epub 2014 Feb 21.

36.

HER2/ErbB2 activates HSF1 and thereby controls HSP90 clients including MIF in HER2-overexpressing breast cancer.

Schulz R, Streller F, Scheel AH, Rüschoff J, Reinert MC, Dobbelstein M, Marchenko ND, Moll UM.

Cell Death Dis. 2014 Jan 2;5:e980. doi: 10.1038/cddis.2013.508.

37.

Damage-induced DNA replication stalling relies on MAPK-activated protein kinase 2 activity.

Köpper F, Bierwirth C, Schön M, Kunze M, Elvers I, Kranz D, Saini P, Menon MB, Walter D, Sørensen CS, Gaestel M, Helleday T, Schön MP, Dobbelstein M.

Proc Natl Acad Sci U S A. 2013 Oct 15;110(42):16856-61. doi: 10.1073/pnas.1304355110. Epub 2013 Sep 30.

38.

Identification of a microRNA expression signature for chemoradiosensitivity of colorectal cancer cells, involving miRNAs-320a, -224, -132 and let7g.

Salendo J, Spitzner M, Kramer F, Zhang X, Jo P, Wolff HA, Kitz J, Kaulfuß S, Beißbarth T, Dobbelstein M, Ghadimi M, Grade M, Gaedcke J.

Radiother Oncol. 2013 Sep;108(3):451-7. doi: 10.1016/j.radonc.2013.06.032. Epub 2013 Aug 7.

PMID:
23932154
39.

Interchanging heads: p53 re-composes the DREAM/MMB complex to repress transcription.

Dobbelstein M.

Cell Cycle. 2013 Jan 1;12(1):11. doi: 10.4161/cc.23169. Epub 2012 Dec 19. No abstract available.

40.

HSP90 inhibitor antagonizing MIF: The specifics of pleiotropic cancer drug candidates.

Schulz R, Dobbelstein M, Moll UM.

Oncoimmunology. 2012 Nov 1;1(8):1425-1426.

41.

A killer promoting survival: p53 as a selective means to avoid side effects of chemotherapy.

Kranz D, Dobbelstein M.

Cell Cycle. 2012 Jun 1;11(11):2053-4. doi: 10.4161/cc.20698. Epub 2012 Jun 1. No abstract available.

PMID:
22622088
42.

Doxorubicin-induced activation of NF-κB in melanoma cells is abrogated by inhibition of IKKβ, but not by a novel IKKα inhibitor.

Pletz N, Schön M, Ziegelbauer K, Emmert S, Liu N, Dobbelstein M, Schön MP.

Exp Dermatol. 2012 Apr;21(4):301-4. doi: 10.1111/j.1600-0625.2012.01440.x. Epub 2012 Feb 10.

PMID:
22320445
43.

Inhibiting the HSP90 chaperone destabilizes macrophage migration inhibitory factor and thereby inhibits breast tumor progression.

Schulz R, Marchenko ND, Holembowski L, Fingerle-Rowson G, Pesic M, Zender L, Dobbelstein M, Moll UM.

J Exp Med. 2012 Feb 13;209(2):275-89. doi: 10.1084/jem.20111117. Epub 2012 Jan 23. Erratum in: J Exp Med. 2012 Mar 12;209(3):640.

44.

MicroRNA-449 in cell fate determination.

Lizé M, Klimke A, Dobbelstein M.

Cell Cycle. 2011 Sep 1;10(17):2874-82. Epub 2011 Sep 1. Review.

PMID:
21857159
45.

Telethonin deficiency is associated with maladaptation to biomechanical stress in the mammalian heart.

Knöll R, Linke WA, Zou P, Miocic S, Kostin S, Buyandelger B, Ku CH, Neef S, Bug M, Schäfer K, Knöll G, Felkin LE, Wessels J, Toischer K, Hagn F, Kessler H, Didié M, Quentin T, Maier LS, Teucher N, Unsöld B, Schmidt A, Birks EJ, Gunkel S, Lang P, Granzier H, Zimmermann WH, Field LJ, Faulkner G, Dobbelstein M, Barton PJ, Sattler M, Wilmanns M, Chien KR.

Circ Res. 2011 Sep 16;109(7):758-69. doi: 10.1161/CIRCRESAHA.111.245787. Epub 2011 Jul 28.

46.

Non-hominid TP63 lacks retroviral LTRs but contains a novel conserved upstream exon.

Beyer U, Dobbelstein M.

Cell Cycle. 2011 Jun 15;10(12):1905-11. Epub 2011 Jun 15.

PMID:
21558811
47.

Anthracyclines induce the accumulation of mutant p53 through E2F1-dependent and -independent mechanisms.

Bug M, Dobbelstein M.

Oncogene. 2011 Aug 18;30(33):3612-24. doi: 10.1038/onc.2011.72. Epub 2011 Mar 28.

PMID:
21441950
48.

Endogenous retrovirus drives hitherto unknown proapoptotic p63 isoforms in the male germ line of humans and great apes.

Beyer U, Moll-Rocek J, Moll UM, Dobbelstein M.

Proc Natl Acad Sci U S A. 2011 Mar 1;108(9):3624-9. doi: 10.1073/pnas.1016201108. Epub 2011 Feb 7.

49.

While p73 is essential, p63 is completely dispensable for the development of the central nervous system.

Holembowski L, Schulz R, Talos F, Scheel A, Wolff S, Dobbelstein M, Moll U.

Cell Cycle. 2011 Feb 15;10(4):680-9. Epub 2011 Feb 15.

50.

MicroRNA-449a levels increase by several orders of magnitude during mucociliary differentiation of airway epithelia.

Lizé M, Herr C, Klimke A, Bals R, Dobbelstein M.

Cell Cycle. 2010 Nov 15;9(22):4579-83. Epub 2010 Nov 15.

PMID:
21088493

Supplemental Content

Loading ...
Support Center